The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 320.00
Bid: 321.00
Ask: 323.00
Change: -15.00 (-4.48%)
Spread: 2.00 (0.623%)
Open: 338.50
High: 341.00
Low: 315.00
Prev. Close: 335.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

2 May 2023 07:00

RNS Number : 9857X
Oxford Biomedica PLC
02 May 2023
 

 

 

 

Oxford Biomedica

Total Voting Rights

 

 

Oxford, UK - 2 May 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company's issued share capital as at the close of business on 28 April 2023 consisted of 96,460,891 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

 

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 96,460,891.

 

The above figure (96,460,891) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

For further information, please contact:

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn, Twitter and YouTube.

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVREAESFELEDEAA
Date   Source Headline
9th Mar 20183:42 pmRNSPROPOSED PLACING TO RAISE APPROXIMATELY £20.5M
9th Mar 20183:17 pmRNSPROPOSED PLACING TO RAISE APPROXIMATELY £20.5M
1st Mar 20189:33 amRNSTotal Voting Rights
28th Feb 20187:15 amRNSHardman & Co Res: BIVV deal establishes structure
23rd Feb 20182:03 pmRNSDirector/PDMR Shareholding
20th Feb 20182:12 pmRNSHoldings in Company
15th Feb 20187:00 amRNSBioverativ Collaboration and Licence Agreement
1st Feb 201811:28 amRNSTotal Voting Rights
23rd Jan 20189:45 amRNS£3 million Innovate UK grant
23rd Jan 20189:30 amRNSDirector Dealings / Market Share Purchase
17th Jan 20187:00 amRNSKymriah receives Priority Review for adult DLBCL
9th Jan 20189:54 amRNSBLOCK LISTING RETURN
9th Jan 20189:54 amRNSBLOCK LISTING RETURN
3rd Jan 20181:33 pmRNSHolding(s) in Company
2nd Jan 20189:49 amRNSTotal Voting Rights
20th Dec 201711:22 amRNSDirector Dealings / Market Share Purchase
11th Dec 20177:08 amRNSPrimary analysis results from JULIET trial
1st Dec 201710:16 amRNSTotal Voting Rights
23rd Nov 201711:29 amRNSDirector Dealings / Market Share Purchase
9th Nov 20177:00 amRNSOXB to present at Jefferies Healthcare Conference
6th Nov 201712:06 pmRNSHoldings in Company
6th Nov 20177:37 amRNSCTL019 MAA submission to the EMA
1st Nov 20179:19 amRNSTotal Voting Rights
31st Oct 20174:01 pmRNSKymriah submitted to FDA for adults with r/r DLBCL
23rd Oct 201711:27 amRNSDirector Dealings / Market Share Purchase
2nd Oct 201711:21 amRNSTotal Voting Rights
26th Sep 20172:55 pmRNSDirector Dealings / Market Share Purchase
26th Sep 20179:37 amRNSLong Term Incentive Plan Option Grant
25th Sep 20173:05 pmRNSBlock listing application
25th Sep 20179:46 amRNSCantor Fitzgerald Healthcare Conference 2017
22nd Sep 201712:36 pmRNSDirector Dealings
20th Sep 20173:25 pmRNSHolding(s) in Company
19th Sep 20178:58 amRNSDirector Dealings
15th Sep 20179:21 amRNSDirector/PDMR Shareholding
12th Sep 20177:15 amRNSHardman Research: New advanced therapies era
7th Sep 201710:11 amRNSHoldings in Company
5th Sep 201711:45 amRNSDirector/PDMR Shareholding
5th Sep 201711:39 amRNSDirector/PDMR Shareholding
5th Sep 20177:00 amRNSOXB to Present at Rodman & Renshaw Conference
1st Sep 20179:25 amRNSTotal Voting Rights
30th Aug 20174:34 pmRNSCTL019 receives FDA approval
29th Aug 20177:00 amRNSStuart Paynter starts as new CFO
24th Aug 201710:41 amRNSHardman Research: Ready for CTL019 approval
23rd Aug 201710:31 amRNSDirector Dealings / Market Share Purchase
22nd Aug 201710:35 amRNSDirector Dealings / Market Share Sale and Purchase
17th Aug 20177:00 amRNSInterim Results
11th Aug 20177:00 amRNSOXB announces Innovate UK £2m collaboration
7th Aug 20179:05 amRNSHolding(s) in Company
7th Aug 20177:00 amRNSMHRA Licence For Commercial Supply
1st Aug 20179:19 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.